Evidence map›Paper›PMID 35008336›Full record

ReviewCancers2021

Survival Outcomes after Hyperthermic Intraperitoneal Chemotherapy for a First Ovarian Cancer Relapse: A Systematic Evidence-Based Review.

Jean-Marc Classe, Bernard Asselain, Loic Campion, Dominique Berton, Jean-Sébastien Frenel, Fabrice Lécuru, Gwenael Ferron, Laurence Gladieff, Charlotte Bourgin, Cecile Loaec

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Jean-Marc ClasseDepartment of Surgery, Institut de Cancerologie de l'Ouest, Boulevard Professor Monod, 44805 Saint Herblain, France.ORCID 0000-0002-6167-5832
Bernard AsselainDepartment of Statistics, Arcagy-Gyneco, 75008 Paris, France.
Loic CampionDepartment of Statistics, Institut de Cancerologie de l'Ouest, Boulevard Professeur Monod, 44805 Saint Herblain, France.ORCID 0000-0003-4903-0908
Dominique BertonDepartment of Medical Oncology, Institut de Cancerologie de l'Ouest, Boulevard Professeur Monod, 44805 Saint Herblain, France.
Jean-Sébastien FrenelDepartment of Medical Oncology, Institut de Cancerologie de l'Ouest, Boulevard Professeur Monod, 44805 Saint Herblain, France.
Fabrice LécuruDepartment of Surgery, Institut Curie, Rue d'Ulm, 75005 Paris, France.
Gwenael FerronDepartment of Surgery, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, 31100 Toulouse, France.
Laurence GladieffDepartment of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, 31100 Toulouse, France.
Charlotte BourginDepartment of Surgery, Institut de Cancerologie de l'Ouest, Boulevard Professor Monod, 44805 Saint Herblain, France.
Cecile LoaecDepartment of Surgery, Institut de Cancerologie de l'Ouest, Boulevard Professor Monod, 44805 Saint Herblain, France.
Institut de Cancérologie de l'Ouest · FRInstitut Claudius Regaud · FRArcagy Gineco · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHyperthermic intraperitoneal chemotherapy (HIPEC) is routinely used in the treatment of a first ovarian cancer relapse.

methodsThis systematic review, in accordance with Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, aimed to assess the quality of scientific proof of the survival benefits of HIPEC, using Medline and Google Scholar. Qualitative analysis using the Oxford CEBM Levels of Evidence 2011 grading is reported.

resultsOf 469 articles identified, 23 were included; 15 based on series of patients treated with HIPEC without a control group, and 8 case control series of patients treated with or without HIPEC. The series without a control group showed median overall survival (OS) ranged from 23.5 to 63 months, highlighting a broad standard deviation. Considering the case control series, OS was significantly better in the HIPEC group in 5 studies, and similar in 1. The current review showed considerable heterogeneity and biases, with an Oxford Level of Evidence grading of 4 for 22 selected series and 2 for one.

conclusionsThere is no strong evidence to suggest efficacy of HIPEC in improving survival of patients treated for a first relapse of ovarian cancer due to the low quality of the data.

Indexed as

disease-free survivalfirst relapsehyperthermic intraperitoneal chemotherapyovarian cancerprogression-free survivalsecondary surgery

Identifiers

PMID35008336
PMCPMC8750536
OpenAlexW4206250999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.